Nov. 29, 2020
by Andrii Buvailo
Biopharma insight
Table of Contents: Introduction The abundance of venture capital, major funding rounds New AI-driven biotech startups founded in 2020 Notable …
July 1, 2020
by David Shlaes
Biopharma insight
(This post originally appeared on David Shlaes's personal blog) The US FDA just published an analysis of antibiotic development looking back …
June 19, 2020
by Irina Bilous
Biopharma insight
Using virtual reality (VR) for manipulating 3D models of molecules in the context of drug design is an emerging technological …
May 11, 2020
by Andrii Buvailo
Interview
Canada has a firm place in the global life sciences ecosystem, being the tenth largest market for pharmaceutical sales, and …
May 1, 2020
by Andrii Buvailo
Interview
There is a great deal of hype and a lot of misconceptions among life science experts as to how AI …
March 18, 2020
by Irina Bilous
Biopharma insight
The microbiome is implicated in a number of metabolic pathways and communicates closely with our body in health and diseases. …
March 4, 2020
by Irina Bilous
Biopharma insight
Alongside the topic of gene editing technologies that keeps making headlines these days, there is also a wave of breakthroughs …
Feb. 21, 2020
by Cathal Strain
Biopharma insight
Pharmaceutical manufacturers find themselves at a critical juncture. In the past 30 years, pharma has seen some significant shifts. Consider …
Feb. 19, 2020
by Irina Bilous
Biopharma insight
A transformative technology for gene editing - clustered regularly interspaced short palindromic repeats (CRISPR) -- has become ubiquitous, at least …
Feb. 17, 2020
by Rasim Shah
Biopharma insight
As we enter a new decade, our belief in the the impact of Artificial intelligence (AI) is only getting stronger. …
Feb. 9, 2020
by Irina Bilous
Biopharma insight
The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some …
Jan. 2, 2020
by Andrii Buvailo
Biopharma insight
There is a plethora of analytics reports, including ones by Deloitte, DKV Global, and Ernst and Young, all pointing out …